ImmunoGen (IMGN) Scheduled to Post Quarterly Earnings on Friday

ImmunoGen (NASDAQ:IMGN) is scheduled to be posting its quarterly earnings results before the market opens on Friday, February 8th. Analysts expect ImmunoGen to post earnings of ($0.33) per share for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

IMGN stock opened at $5.49 on Thursday. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.59 and a quick ratio of 4.56. ImmunoGen has a 12 month low of $3.80 and a 12 month high of $13.41. The company has a market capitalization of $720.11 million, a PE ratio of -7.32 and a beta of 2.36.

A number of equities analysts have recently commented on the stock. ValuEngine upgraded shares of ImmunoGen from a “hold” rating to a “buy” rating in a research report on Wednesday, October 17th. William Blair restated an “outperform” rating on shares of ImmunoGen in a research report on Monday, October 22nd. HC Wainwright set a $18.00 price objective on shares of ImmunoGen and gave the company a “buy” rating in a research report on Monday, October 22nd. BidaskClub lowered shares of ImmunoGen from a “hold” rating to a “sell” rating in a research report on Wednesday, October 24th. Finally, Piper Jaffray Companies set a $14.00 price objective on shares of ImmunoGen and gave the company a “buy” rating in a research report on Sunday, December 2nd. One investment analyst has rated the stock with a sell rating, four have given a hold rating and seven have issued a buy rating to the stock. ImmunoGen presently has a consensus rating of “Buy” and an average price target of $14.60.

COPYRIGHT VIOLATION NOTICE: This article was published by Markets Daily and is owned by of Markets Daily. If you are reading this article on another website, it was stolen and reposted in violation of international trademark and copyright laws. The correct version of this article can be accessed at https://www.themarketsdaily.com/2019/02/07/immunogen-imgn-scheduled-to-post-quarterly-earnings-on-friday.html.

About ImmunoGen

ImmunoGen, Inc, a clinical-stage biotechnology company, focuses on developing antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; IMGN779 that is in Phase I clinical trial for the treatment of acute myeloid leukemia (AML); and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm, as well as coltuximab ravtansine, a CD19-targeting ADC, which is in Phase II trial for DLBCL.

Read More: Bear Market – How and Why They Occur

Earnings History for ImmunoGen (NASDAQ:IMGN)

Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply